Your browser doesn't support javascript.
loading
Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.
Lam, Clarissa; Ha, Kristal; Hakam, Ardeshir; Shahzad, Mian M K.
Afiliação
  • Lam C; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA.
  • Ha K; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA.
  • Hakam A; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Shahzad MMK; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Oncologic Sciences, University of South Florida, Morsani School of Medicine, Tampa, FL, USA.
Gynecol Oncol Rep ; 41: 100992, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35540026
ABSTRACT
•Management of platinum refractory ovarian cancer is challenging.•Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy.•Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article